95 filings
Page 3 of 5
6-K
r8omal6l4sa2v1 53
30 Nov 21
ERYTECH Secures US Patent Directed to Sequential Use of Methioninase & Asparaginase against Solid Tumors
10:32am
6-K
4w5yq8l
16 Nov 21
Current report (foreign)
2:22pm
6-K
8lx05gico 1tmgmxm
25 Oct 21
ERYTECH Announces Results from TRYbeCA-1 Phase 3
10:59am
6-K
kq6bhgvijd0ylqw99juv
5 Oct 21
ERYTECH Announces Maximum Tolerated Dose Declared in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer
12:34pm
6-K
cmbva3a j7pzlmcy8
21 Sep 21
ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2021
9:42am
6-K
ruiuobx
20 Sep 21
I.Certification of the Person Responsible for the Half-year Financial Report
1:37pm
6-K
r4sny8jeixw r9ns01x
30 Jul 21
ERYTECH Granted U.S. FDA Fast Track Designation for Eryaspase in Hypersensitive ALL
10:09am
6-K
9xjgr 47d
26 Jul 21
Current report (foreign)
11:47am
6-K
5yc70q6 qpwtb88gep6s
29 Jun 21
Current report (foreign)
8:18am
6-K
50orld dsapbay
26 May 21
Live webcast of the Shareholders’ Meeting
9:55am
6-K
3sm4lcwehk l6cga
7 May 21
ERYTECH Provides Business Update and Reports Financial Results for the First Quarter of 2021
6:13am
6-K
15t4 x1g4
3 May 21
ERYTECH Announces $30.0 Million
5:20pm
6-K
76giqrv40tx7r
3 May 21
ERYTECH Reports Cash Balance at End of Q1 2021
6:07am
6-K
uv8 4xxbq9uctt2df
21 Apr 21
ERYTECH Requested a Pre-BLA Meeting with the FDA
8:01am
6-K
7bz74d
19 Apr 21
ERYTECH Announces Completion of First Cohort in a Phase 1 Investigator Sponsored Trial of
9:48am
6-K
74m31wqaho7x7wjo 8k
9 Mar 21
ERYTECH Provides Business Update and Reports Financial Results for the Full Year 2020
9:55am
6-K
2qp3owjw2ut6 pps
8 Feb 21
ERYTECH Announces TRYbeCA-1 Phase 3 Trial
9:15am
6-K
zvmug1qp
27 Jan 21
ERYTECH Highlights 2021 Milestones
10:17am
6-K
6kpd7nowamp8 4k
15 Jan 21
ERYTECH Announces First Patient Enrolled in Eryaspase in First-Line Pancreatic Cancer
12:35pm
6-K
lf15l3f z53e0
15 Dec 20
ERYTECH Completes Enrollment in TRYbeCA-1
8:16am